• Are We on Shaky Ground With Medication Adherence?

    By Gina ShawEmerging data suggest that traditional medication-adherence metrics and strategies are failing to capture—and address—the real drivers of whether patients take lifesaving therapies.Analyses of Medicare Part D Star Ratings, for example, show that despite steady gains in proportion of days covered (PDC), the share of high-performing plans has sharply declined as incentives wane and PDC approaches a ceiling, prompting calls for new quality measures. Meanwhile, electronic mon
  • Targeting CD4 to Treat HIV

    By Meaghan Lee CallaghanThere are integrase inhibitors, there is a capsid inhibitor, and there is ibalizumab-uiyk (Trogarzo, TaiMed Biologics), a CD4-directed post-attachment HIV-1 inhibitor.Although ibalizumab is FDA-approved for people with multidrug-resistant HIV who have failed other treatment options, TaiMed Biologics has a new drug combination using the same mechanism but that company CEO Jimmy Chang, PhD, said he hopes will apply to the larger population of people living with HIV.Dr. Chan

Follow @newsl_pharmacy on Twitter!